Loading
Life sciences · Journal article
Psycho-oncologie · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
We developed and temporally internally validated a pretreatment nomogram for predicting pathological complete response (pCR) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer and examined cross-sectional associations among systemic inflammation, model-derived pCR probability, and baseline psychosocial burden. This ambispective single-center cohort included women receiving neoadjuvant chemotherapy plus HER2-directed therapy followed by surgery. Patients treated from January 2019 to December 2023 formed the training cohort (n=198), and those treated from January to August 2024 formed a same-center temporal validation cohort (n=48). Psychosocial support need was defined as Distress Thermometer score ≥4, Hospital Anxiety and Depression Scale-Anxiety score ≥8, or Hospital Anxiety and Depression Scale-Depression score ≥8. Among 315 screened patients, 246 had complete data. pCR occurred in 72 training patients (36.36%) and 17 validation patients (35.42%). The final nomogram retained tumor size, clinical nodal status, hormone receptor status, and standardized neutrophil-to-lymphocyte ratio (NLR). Discrimination was acceptable in the training cohort (AUC=0.776; optimism-corrected AUC=0.758) and temporal validation cohort (AUC=0.769), although validation estimates were imprecise. Overall, 125 patients (50.81%) met the psychosocial support-need endpoint. Lower NLR-containing predicted pCR probability was associated with support need (OR=1.49 per 0.10 decrease), but this association attenuated after direct NLR adjustment (OR=1.13), indicating limited incremental psychosocial value beyond inflammation. The nomogram showed acceptable pretreatment pCR prediction performance, whereas psychosocial associations should be interpreted as non-causal clinical-inflammatory correlations requiring prospective multicenter validation.